@Article {Yamashita2100880，作者= {yamashita，Masahiro和Niisato，Miyuki和Kawasaki，Yasushi和Karaman，Sinem和Robciuc，Marius R.和Shibata，Yuji和Ishida，yoji和Nishio，Ryosuke和Masuda，Tamotsu和Sugai，Tamotsu和ONO，Masao和Tuder，Rubin M.和Alitalo，Kari和Yamauchi，Kohei}，标题= {Vegf-C / Vegfr-3信号传导在巨噬细胞中改善急性肺损伤}，Elocation-Id = {2100880}，年= {2021}，DOI = {10.11880-2021}，出版商= {欧洲呼吸社会}，摘要= {理论从急性肺损伤中成188bet官网地址功恢复需要抑制中性粒细胞流入和凋亡中性粒细胞的间隙。然而，恢复的机制仍然不清楚。我们研究了血管内皮生长因子受体-3（VEGFR-3）/ VEGF-C信号在脂多糖诱导的肺损伤中的巨噬细胞中的改进效果。方法鼻内注射到野外 -类型和转基因小鼠。VEGF-C / VEGFR-3信号传导功能实验的增益和损失使用腺病毒介导的VEGF-C（AD-VEGF-C载体）和可溶性VEGFR-3的鼻内递送，或抗VEGFR-3阻断抗体和在骨髓细胞中缺失VEGFR-3的小鼠。测量和主要结果肺损伤的早期阶段通过VEGF-C的过度表达具有显着缓解，随着BRONCOALVELAR灌洗液（BALF）白细胞介素（IL）-10的增加，但通过VEGFR-3抑制在施用AD-SVEGFR-3载体时在后期抑制恶化。将抗VEGFR-3抗体注射到小鼠中，分辨率相位抑制肺损伤的恢复。VEGFR-3已缺失的小鼠的存活时间较短，而分辨率阶段的肺肺损伤更严重。肺泡巨噬细胞在分辨率阶段消化了大多数外部凋亡中性粒细胞，VEGF-C / VEGFR-3通过巨噬细胞中整合蛋白αv的上调来增加效力细胞细胞增多。 We also found that incubation with BALF from acute respiratory distress syndrome (ARDS) patients, but not from controls, decreases VEGFR-3 expression and the efficiency of IL-10 expression and efferocytosis in human monocyte-derived macrophages.Conclusions VEGFR-3/VEGF-C signaling in macrophages ameliorates experimental lung injury. This mechanism may provide an explanation also for ARDS resolution.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Yamashita has nothing to disclose.Conflict of interest: Dr. Niisato has nothing to disclose.Conflict of interest: Dr. Kawasaki has nothing to disclose.Conflict of interest: Dr. Karaman has nothing to disclose.Conflict of interest: Dr. Robciuc has nothing to disclose.Conflict of interest: Dr. Shibata has nothing to disclose.Conflict of interest: Dr. Ishida has nothing to disclose.Conflict of interest: Dr. Nishio has nothing to disclose.Conflict of interest: Dr. Masuda has nothing to disclose.Conflict of interest: Dr. Sugai has nothing to disclose.Conflict of interest: Dr. Ono has nothing to disclose.Conflict of interest: Dr. Tuder has nothing to disclose.Conflict of interest: Dr. Alitalo has nothing to disclose.Conflict of interest: Dr. Yamauchi has nothing to disclose.}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/early/2021/08/19/13993003.00880-2021}, eprint = {//www.qdcxjkg.com/content/early/2021/08/19/13993003.00880-2021.full.pdf}, journal = {European Respiratory Journal} }